Sumitomo Pharma Co., Ltd. (DNPUF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Osaka, Japan. El CEO actual es Toru Kimura.
DNPUF tiene fecha de IPO 2012-01-17, 4,980 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $4.41B.
Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical manufacturer and supplier operating globally across North America, China, and other international markets. The company develops and markets a diverse therapeutic portfolio including treatments for Parkinson's disease, depression, type 2 diabetes, cancer, infectious diseases, and cardiovascular conditions, alongside specialty pharmaceuticals for rare diseases such as Fabry disease. Beyond pharmaceuticals, Sumitomo Pharma produces food ingredients and additives, chemical materials for industrial and personal care applications, and veterinary medicines for both companion and livestock animals. Founded in 1897 and headquartered in Osaka, the company maintains strategic partnerships with leading research institutions including Kyoto University, RIKEN, and the Center for iPS Cell Research, as well as collaborations with biotech firms such as Roivant Sciences. As a subsidiary of Sumitomo Chemical Company, Limited, Sumitomo Pharma combines established pharmaceutical expertise with innovation in emerging therapeutic areas.
